The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., & Nebert, D. W. (2004) · Pharmacogenetics · doi:10.1097/00008571-200401000-00001 · Cited by 1,027
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., & Goldstein, J. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40694-6 · Cited by 956
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
THE INCIDENCE OF ALKAPTONURIA : A STUDY IN CHEMICAL INDIVIDUALITY.
Garrod, A. (1902) · The Lancet · doi:10.1016/s0140-6736(01)41972-6 · Cited by 789
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Research works printed but not linked: 18
- Van Schaik, 2003, CYP3A4, CYP3A5 and MDR-1 variant alleles in the Dutch Caucasian population, Clin. Pharmacol. Ther., 73, 42, 10.1016/S0009-9236(03)90510-8 · doi:10.1016/s0009-9236(03)90510-8
- Snyder, 1932, Studies on human inheritance. IX. The inheritance of taste deficiency in man, Ohio J. Sci., 32, 436
- Eichelbaum, M. et al. (1978) A probably genetic defect in the metabolism of sparteine. In Biological Oxidation of Nitrogen (Gorrow, J.W., ed), pp. 113–118, Elsevier.
- Dayer, 1982, Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers, Eur. J. Drug Metab. Pharmacokinet., 7, 73, 10.1007/BF03189547 · doi:10.1007/bf03189547
- Lou, 1987, Low frequency of slow debrisoquine hydroxylation in a native Chinese population, Lancet, 2, 852
- Yue, 1989, Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese, Lancet, 2, 870, 10.1016/S0140-6736(89)93041-9 · doi:10.1016/s0140-6736(89)93041-9
- Mura, 1991, Distinct phenotypes and genotypes of debrisoquine hydroxylation among Europeans and Chinese, Br. J. Clin. Pharmacol., 32, 135, 10.1111/j.1365-2125.1991.tb05629.x · doi:10.1111/j.1365-2125.1991.tb05629.x
- Agundez, 1994, Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations, Clin. Pharmacol. Ther., 55, 412, 10.1038/clpt.1994.50 · doi:10.1038/clpt.1994.50
- Küpfer, 1979, Family study of a genetically determined deficiency of mephenytoin hydroxylation to p-hydroxymephenytoin in man, Pharmacologist, 21, 173
- Relling, 1990, Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily, J. Pharmacol. Exp. Ther., 252, 442
- Yamano, 1989, cDNA and deduced amino acid sequences of human P450 IIA3 (CYP2A3), Nucleic Acids Res., 17, 4888, 10.1093/nar/17.12.4888 · doi:10.1093/nar/17.12.4888
- Dickson, 2003, Genetics of response to proton pump inhibitor therapy, Am. J. Pharmacogenomics, 3, 303, 10.2165/00129785-200303050-00002 · doi:10.2165/00129785-200303050-00002
- Takahashi, 2003, Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin, Pharmacogenomics J., 3, 202, 10.1038/sj.tpj.6500182 · doi:10.1038/sj.tpj.6500182
- Hallberg, 2002, The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan left ventricular hypertrophy investigation vs Atenolol (SILVHIA) trial, J. Hypertens., 20, 2089, 10.1097/00004872-200210000-00030 · doi:10.1097/00004872-200210000-00030
- Barclay, 2003, Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status, Pharmacogenetics, 13, 627, 10.1097/00008571-200310000-00006 · doi:10.1097/00008571-200310000-00006
- Dalen, 1977, Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine, Ther. Drug Monit., 19, 543, 10.1097/00007691-199710000-00011 · doi:10.1097/00007691-199710000-00011
- de Leon, 2003, Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers, J. Clin. Psychopharmacol., 23, 420, 10.1097/01.jcp.0000085421.74359.60 · doi:10.1097/01.jcp.0000085421.74359.60
- Lesko, 2003, Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop, J. Clin. Pharmacol., 43, 342, 10.1177/0091270003252244 · doi:10.1177/0091270003252244
Cited by
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312808 · Cited by 1,070
Gut microorganisms, mammalian metabolism and personalized health care
Nicholson, J. K., Holmes, E., & Wilson, I. D. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1152 · Cited by 945
Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes
Waxman, D. J., & Holloway, M. G. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056705 · Cited by 815
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Self-citationPharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Arranz, M. J., & de Leon, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 351
Metadata
- Authors
- Ingelman-Sundberg, M.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 25
- Issue
- 4
- Pages
- 193-200
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2164705071
- Cited by
- 676
- References
- 66
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. https://app.cochat.ai/papers/10.1016/j.tips.2004.02.007
- The paper
- Ingelman-Sundberg, M. (2004). Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2004.02.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
